Jen Butler, chief commercial officer, Pleio, discusses the effectiveness of peer-to-patient outreach when starting specialty medications.
News
Advertisement
The tool will focus on educational resources by offering both in-person and telehealth support for individuals living in the United States.
Advertisement
In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Brad Stewart, BDO’s national life sciences co-leader, details the Biosecure Act, including the ways pharma companies are preparing for it, especially from a compliance standpoint.
The latest news for pharma industry insiders.
Jen Butler, chief commercial officer, Pleio, discusses how the company’s GoodStart programs help patients navigate specialty pharmacies.
The Beijing location represents the sixth worldwide.
Advertisement
The latest news for pharma industry insiders.
What drivers impact the differences in expenditures?
In the fourth part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Brad Stewart, BDO’s national life sciences co-leader, addresses how AI can help support pharma leaders with managing their supply chains and addressing potential material shortages.
The latest news for pharma industry insiders.
Advertisement
Jonathan James, CEO, Hope Charities, discusses how, despite policy advancements, millions of people still face barriers to healthcare access.
A Day 3 presentation dives into the impact of copay accumulators, maximizers, and AFPs on driving cost savings.
The latest news for pharma industry insiders.
Jonathan James, CEO, Hope Charities, discusses the challenge of nonprofits securing sustainable funding while ensuring patients are aware of available assistance.
The presentation suggests ways to educate patients on the options available to them, with the hope of ultimately improving health outcomes.
The latest news for pharma industry insiders.
Jonathan James, CEO, Hope Charities, discusses the critical importance of maintaining access to life-saving medications for patients with rare diseases to lead productive lives.
The session provides an overview of the uninsured population, and also tackles challenges faced by patients when it comes to accessing PAPs.
The latest news for pharma industry insiders.
A roundtable explores how patient access needs are being measured, while also discussing the value of affordability in decision-making.
Jonathan James, CEO, Hope Charities, discusses reimbursement challenges and barriers to care in patients requiring life-saving medications.
The conference’s first panel offers insight on the current state of awareness among beneficiaries of the Part D cap and Medicare Prescription Payment Plan via the PAN Foundation’s latest research.
The latest news for pharma industry insiders.
The conference’s opening session highlights the sector’s current landscape of healthcare coverage and access.
In the third part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Brad Stewart, BDO’s national life sciences co-leader, outlines the ways that tariffs disrupt pharma supply chains, along with how leaders can evaluate and prepare for the resulting challenges.
The latest news for pharma industry insiders.
Why driving results from such strategies—amid industry disruption—will be critical to success.
In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jason C. Foster, CEO of Ori Biotech, comments on how he envisions automation in the CAR-T manufacturing space playing a role in improving efficiency, reducing costs, and ultimately, expanding patient access.
The latest news for pharma industry insiders.
The thermal packaging company not only bolsters its APAC presence—it also grows its influence in the life sciences’ temperature-monitoring logistics sector.
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
The Key to Connecting with Patients: Pharma's Market Access Transformation
2
Alcami Brings Third Sterile Fill-Finish Line Online. Expanding Clinical-to-Commercial Capacity
3
The Next Era of Drug Safety is in Intelligent Action
4
Novartis’ $23 Billion Manufacturing Investment Anchors Industry Shift Toward US Onshoring
5